Thalidomide	O
and	O
angiostatin	O
inhibit	O
tumor	B-Cancer
growth	O
in	O
a	O
murine	O
xenograft	B-Cancer
model	O
of	O
human	O
cervical	B-Cancer
cancer	I-Cancer
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
impact	O
of	O
thalidomide	O
and	O
angiostatin	O
on	O
tumor	B-Cancer
growth	O
,	O
angiogenesis	O
,	O
and	O
apoptosis	O
in	O
a	O
xenograft	B-Cancer
model	O
of	O
cervical	B-Cancer
cancer	I-Cancer
.	O

METHODS	O
:	O
Human	O
umbilical	O
endothelial	B-Cell
cells	I-Cell
were	O
treated	O
with	O
angiostatin	O
or	O
thalidomide	O
and	O
bFGF	O
-	O
induced	O
proliferation	O
was	O
assessed	O
with	O
the	O
MTT	O
assay	O
.	O

Human	O
cervical	B-Cell
cancer	I-Cell
cells	I-Cell
(	O
CaSki	B-Cell
and	O
SiHa	B-Cell
)	O
were	O
injected	O
into	O
the	O
flanks	B-Organism_subdivision
of	O
nude	O
mice	O
.	O

After	O
tumors	B-Cancer
developed	O
,	O
mice	O
were	O
treated	O
with	O
angiostatin	O
20	O
mg	O
/	O
kg	O
/	O
day	O
or	O
thalidomide	O
200	O
mg	O
/	O
kg	O
/	O
day	O
for	O
30	O
days	O
.	O

Fractional	O
tumor	B-Cancer
growth	O
was	O
determined	O
and	O
immunohistochemical	O
analysis	O
of	O
tumors	B-Cancer
was	O
used	O
to	O
determine	O
degree	O
of	O
angiogenesis	O
.	O

TUNEL	O
assay	O
was	O
used	O
to	O
assess	O
apoptosis	O
.	O

RESULTS	O
:	O
Angiostatin	O
inhibited	O
endothelial	B-Cell
cell	I-Cell
proliferation	O
by	O
50	O
-	O
60	O
%	O
.	O

Thalidomide	O
had	O
no	O
direct	O
effect	O
on	O
endothelial	B-Cell
cells	I-Cell
.	O

Angiostatin	O
and	O
thalidomide	O
both	O
inhibited	O
tumor	B-Cancer
growth	O
by	O
about	O
55	O
%	O
.	O

We	O
found	O
no	O
additive	O
or	O
synergistic	O
effect	O
when	O
the	O
two	O
agents	O
were	O
combined	O
.	O

Both	O
agents	O
inhibited	O
angiogenesis	O
and	O
induced	O
apoptosis	O
when	O
compared	O
to	O
tumors	B-Cancer
from	O
control	O
animals	O
.	O

CONCLUSIONS	O
:	O
Angiostatin	O
and	O
thalidomide	O
inhibit	O
tumor	B-Cancer
growth	O
,	O
angiogenesis	O
,	O
and	O
induce	O
apoptosis	O
in	O
this	O
xenograft	B-Cancer
model	O
of	O
cervical	B-Cancer
cancer	I-Cancer
.	O

